Teriflunomide 是一种来氟米特的活性代谢产物，能够抑制嘧啶合成，有效降低T细胞和B细胞增殖，可用于研究类风湿性关节炎。

Teriflunomide is the principal active metabolite of leflunomide, an approved therapy for rheumatoid arthritis and multiple sclerosis.

Teriflunomide primarily acts as an inhibitor of dihydroorotate dehydrogenase (DHODH), a key mitochondrial enzyme involved in the de novo synthesis of pyrimidines in rapidly proliferating cells.?By reducing the activity of high-avidity proliferating T lymphocytes and B lymphocytes, teriflunomide likely attenuates the inflammatory response to autoantigens in MS.Of note, DHODH blockade does not affect resting or homeostatically proliferating hematopoietic cell lines, as pyrimidine pools in these cells can be generated through an alternate "salvage pathway,” which is independent of the DHODH.As a result.Thus, teriflunomide can be considered a cytostatic rather than a cytotoxic drug to leukocytes[1].

163451-81-8

C12H9F3N2O2

270.21

A 77-1726;特立氟胺

DMSO:26 mg/mL (96.22 mM)
Powder: -20°C for 3 years
In solvent: -80°C for 2 years